Company Overview of Crescendo Bioscience, Inc.
Crescendo Bioscience, Inc., a molecular diagnostics company, develops and commercializes quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases in the United States. The company offers Vectra DA, a multi-biomarker blood test for RA disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score to help physicians make more informed treatment decisions. Crescendo Bioscience, Inc. was formerly known as Riley Genomics, Inc. and changed its name to Crescendo Bioscience, Inc. in June 2005. The company was founded in 2002 and is based in South San Francisco, California. Crescendo Bioscience, In...
341 Oyster Point Boulevard
South San Francisco, CA 94080
Founded in 2002
Key Executives for Crescendo Bioscience, Inc.
Co-Founder and Scientific Advisor
Senior Vice President of Medical Affairs
Compensation as of Fiscal Year 2015.
Crescendo Bioscience, Inc. Key Developments
Crescendo Bioscience Appoints Elena Hitraya as Chief Medical Officer, Effective October 1, 2015
Sep 1 15
Crescendo Bioscience announced that Elena Hitraya M.D., Ph.D., has joined the company as the chief medical officer of Crescendo Bioscience, effective October 1, 2015. She will report to Bernie Tobin, president of Crescendo Bioscience. In her new role, Dr. Hitraya will lead efforts to provide professional education initiatives and to expand market access for Vectra DA and the company's pipeline of autoimmune products. She will also be instrumental in efforts to develop other autoimmune products beyond rheumatoid arthritis. Dr. Hitraya comes to Crescendo with more than 25 years of experience in rheumatology and immunology, and she has published extensively. Over the past 11 years, she has held several leadership positions at Genentech, including most recently as group medical director of rheumatology/immunology for the Genentech/Roche group.
Myriad Genetics Appoints Bernard Tobin as President of Crescendo Bioscience, Effective January 5, 2015
Dec 22 14
Myriad Genetics, Inc. announced the appointment of Bernard Tobin as president of Crescendo Bioscience, effective January 5, 2015. He will succeed William Hagstrom, who has chosen to pursue new start-up business and social venture opportunities. Tobin will report to Peter Meldrum, president and CEO, Myriad Genetics. Hagstrom will remain with the company until January 2, 2015 to ensure a smooth transition in leadership. Tobin has held several senior positions at Amgen over the past seven years, including Executive Director of National Accounts, General Manager of both the Netherlands and Brazil and Global Head of Commercial Excellence.
Crescendo Bioscience Presents New Clinical Data on Vectra(R) DA at ACR
Nov 19 14
Crescendo Bioscience presented new data that showed Vectra(R) DA is a better predictor of radiographic progression over two years than other tests used to assess risk of joint damage in rheumatoid arthritis (RA), such as C-reactive protein (CRP). The oral presentation was featured at the 2014 American College of Rheumatology (ACR) Annual Meeting in Boston, Massachusetts. The study included 143 patients with RA who had received a stable treatment and were enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) registry in the United States. Patients were evaluated at their initial visit in the BRASS registry for the Vectra DA score and conventional measures of disease activity, including CRP, DAS28-CRP, CDAI, SDAI and RAPID3, and provided X-rays of hands and wrists at approximately the initial visit and two years later. These data were used to assess the relationship between disease activity and the amount of subsequent new joint damage seen on X-rays (radiographic progression). Another study featured at ACR provided an analysis of radiographic progression in patients with early RA from the Swedish Farmacotherapy (SWEFOT) clinical trial. The Vectra DA test was used to evaluate 220 patients for progression from baseline to Year 1 and from baseline to Year 2. In addition, progression from Year 1 to Year 2 was evaluated for 133 patients who had inadequate initial responses to methotrexate and were treated from month three with the addition of a TNF inhibitor or with triple therapy using methotrexate, sulfasalazine and hydroxychloroquine.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|